Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC22 in chronic hepatitis B
CTR20200363Phase 2Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Mar 2020
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in Chronic Hepatitis B (CHB), sponsored by Ascletis Pharma Inc.. Started Mar 2020; status: completed.
02
Drugs
envafolimab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20200363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200363.